Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HDL [high density lipoprotein] modulation and endothelial function

Trial Profile

HDL [high density lipoprotein] modulation and endothelial function

Phase of Trial: Phase III

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Niacin (Primary) ; Atorvastatin
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Mar 2010 Results presented at 59th Annual Scientific Session of the American College of Cardiology.
    • 02 Nov 2008 Trial end date changed from 1 Jul 2008 to 1 Aug 2008 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top